oral glp 1 pfizer selects new drug for danuglipron | Pharmaceutical Business Review International posted on the topic Pfizer axes oral GLP-1 asset,

10.1038/s41386-019-0531-4 [DOI] [PMC free article] [PubMed] [Google Scholar] Zorrilla, E

These may include: Nausea Vomiting Diarrhea Reduced appetite Feeling full sooner than usual Together, these factors can increase the likelihood of dehydration if you're not intentionally replacing lost fluids

14Love the show

Lawsuits argue that drug manufacturers failed to adequately warn consumers and healthcare providers about the significant risks tied to these drugs

The primary interaction concern is with oral medications that depend on consistent absorption

But Gupta stresses that its unclear what type of generic version will become available, since semaglutide is given at different doses for different conditions, with a range of costs